Monday, May 20, 2013 Last update: 11:34 AM
Company Tech News as it Breaks
Trade Events
bioTheranostics
News articles for bioTheranostics:
Thursday, May 2, 2013
- bioTheranostics’ Prostate Cancer Index Predicts Risk for Prostate Cancer RecurrenceA new molecular test from bioTheranostics—the Prostate Cancer Index—is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk ... read more
Tuesday, March 26, 2013
- bioTheranostics’ CancerTYPE ID® More Accurate than Immunohistochemistry in Diagnosing Metastatic TumorsbioTheranostics’ CancerTYPE® ID molecular cancer classifier demonstrated superior accuracy compared with immunohistochemistry (IHC) in identifying the primary site ... read more
Wednesday, December 5, 2012
- bioTheranostics’ Breast Cancer Index (BCI) Molecular Test Predicts Late Distant Recurrence in Estrogen Receptor-Positive, Lymph Node-Negative Breast CancerA major head-to-head study comparing bioTheranostics’ Breast Cancer Indexsm (BCI) to the Oncotype Dx Breast Cancer Assay and IHC4 for breast cancer ... read more